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Abstract
Objective: The objective of this selective EBM review is to determine whether or not CDK 4/6
inhibitors, in combination with anti-estrogen therapy, improve morbidity and mortality for
women with advanced breast cancer compared to anti-estrogen monotherapy.
Study Design: Systematic review of three randomized-controlled trials. All three articles were
published in English between 2015 and 2016.
Data Sources: Two randomized, double-blinded, placebo-controlled trials and one open-label
randomized controlled trial found using PubMed and NCBI.
Outcomes Measured: Each study assessed morbidity and mortality based on progression-free
survival or overall clinical benefit (stable disease, partial response, or complete response by 24
weeks).
Results: All three studies showed significant prolongation of progression-free survival in patients
that received treatment with anti-estrogen therapy plus an oral CDK 4/6 inhibitor for their
estrogen receptor-positive, HER2neu negative metastatic breast cancer compared to anti-estrogen
therapy alone or with placebo. Cristofanilli et al. found that median progression-free survival
improved from 4.6 months to 9.5 months with combination therapy. Similar results were seen in
Finn et al. with median progression-free survival of 20.2 months in those receiving combination
therapy, compared to 10.2 months in women treated with anti-estrogen therapy alone. In the
study by Hortobagyi et al., the progression-free survival rate at 18 months for those treated with
CDK4/6 inhibitor was 63%, compared to 42.2% in the placebo group.
Conclusions: These studies suggest that cyclin dependent kinase 4/6 inhibitors used in
conjunction with anti-estrogen therapy should be considered as an efficacious treatment regimen
for postmenopausal patients with hormone receptor-positive, HER2neu negative advanced breast
cancer. Finn and Hortobagyi, and colleagues, investigated the use of an aromatase inhibitor,
letrozole, for anti-estrogen therapy. Cristofanilli and colleagues studied the efficacy of an
estrogen receptor downregulator, fulvestrant. Additionally, palbociclib was used for inhibition of
the CDK4/6 pathway in two studies, while ribociclib was used in the other. Improvement in
progression-free survival and overall response was seen in all three studies regardless of the
combination of drugs being used.
Key Words: Cyclic dependent kinase, palbociclib, fulvestrant, advanced breast cancer
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INTRODUCTION
Breast cancer is characterized by the formation and growth of malignant cells within
breast tissue. It is the most commonly diagnosed cancer in women, and the second leading cause
of cancer death in this group.1 Approximately 3.5 million women in the US are living with breast
cancer; it is estimated that another 252,710 new cases will be diagnosed in 2017. 1 In 2010, the
estimated cost of treating breast cancer in the US was ~$16.5 billion, and that number is
expected to increase to $20.5 billion by 2020.2
Breast cancer can be classified as in situ (confined to its site of origin) or invasive
disease, and has multiple molecular subtypes. Age is the most common risk factor for breast
cancer, with the majority of diagnoses made after age 50. Additional risk factors include genetic
tendency, positive family history of breast or ovarian cancer, having dense breasts or prior
benign breast disease, sedentary lifestyle, diet high in saturated fat, excess alcohol consumption,
and the use of HRT.1 Additionally, due to extended exposure to hormones, women who have
early menarche or late menopause are at an increased risk for developing breast cancer.
Mammography has become a useful tool in detecting breast cancer. The American
Cancer Society recommends that women ages 40 to 44 have the choice to start yearly screening
mammograms, and those women 45 and older should be screened annually. 3 At age 55, annual
screenings can continue, or a woman can choose to have the exam performed every two years
instead.3 It is recommended that screening start sooner for high-risk individuals (e.g. strong
family history, known genetic mutation). Breast cancer can be asymptomatic, with the first sign
of disease being an abnormality seen on imaging studies. Those with symptomatic disease might
notice a palpable breast mass, change in breast contour or the overlying skin, or nipple discharge.
Additionally, patients with malignancy may complain of fatigue. Symptoms of advanced breast
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cancer are commonly associated with disease location; breast cancer most commonly
metastasizes to regional lymph nodes, bones, lung, liver and brain. An individual may
subsequently experience lymphadenopathy, bone/back pain, nausea and vomiting, anorexia,
weight loss, dry cough, shortness of breath, or changes in mentation.
Treatment of breast cancer is a multi-factorial approach and can include breast surgery
with lumpectomy or mastectomy, axillary biopsy and resection, radiation to local or metastatic
disease, systemic chemotherapy, and endocrine therapy. Patients with bony disease might also
benefit from bisphosphonate derivatives. When considering clinical treatment, three genetic
distinctions are considered: 1) estrogen receptor status 2) progesterone receptor status, and 3)
HER2neu gene overexpression.4 Of those diagnosed with invasive disease, ~71% are hormone
receptor-positive, HER2neu negative.1 Roughly 5% of women have stage 4 disease at the time of
diagnosis, and the estimated 5-year survival for those with distant metastatic disease is 26%. 5 For
these patients, hormonally directed therapy remains the mainstay of treatment, but is seldom
effective as these patients can quickly develop endocrine resistance. 4,6,7 Managing these resistant
cases continues to be a challenge within the medical community. Alteration in the cell cycle is a
well-known characteristic in the development and spread of cancer. Multiple studies have
investigated the role of various signaling pathways and receptor mutations that contribute to such
cases. Cyclin dependent kinases (CDK) are a group of kinases that work together with regulatory
proteins to control progression through the cell cycle; alteration and activation of the CDK 4/6
axis has been found to be a common feature in hormone receptor-positive cancer.4 Studies have
found that inhibiting this pathway is associated with arresting sensitive human breast cancer cells
in the G1 phase of their cell cycles, with the effect being especially potent in receptor-positive
breast cancers.4 This paper evaluates three randomized controlled trials comparing the efficacy
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of combination therapy with cyclin dependent kinase 4/6 inhibitors and anti-estrogen
medications at improving progression-free survival in patients with advanced disease.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not CDK 4/6
inhibitors, in combination with anti-estrogen therapy, improve morbidity and mortality for
women with advanced breast cancer compared to anti-estrogen monotherapy.
METHODS
The author of this selective review searched articles using PubMed and NCBI. Key words
in the search included cyclin dependent kinase, palbociclib, fulvestrant, and advanced breast
cancer. Articles were considered if they were relevant to the clinical question and included
POEMs, were written in English, and had been published within the last 10 years. Exclusion
criteria included previous Cochrane reviews, as well as previous selective EBM reviews
submitted by prior students. This research study analyzed three RCTs. The population in all three
studies included women over age 18 who had estrogen receptor-positive, HER2neu negative
advanced breast cancer. Two of the three studies, conducted by Finn et al. and Hortobagyi et al.,
evaluated a CDK 4/6 inhibitor plus anti-estrogen therapy as a first-line systemic treatment for
advanced disease, while the other, performed by Cristofanilli and colleagues, included patients
who had metastatic breast cancer that progressed on previous endocrine therapy. Palbociclib or
ribociclib were representative of CDK4/6 inhibitors, while letrozole or fulvestrant were used for
anti-estrogen therapy. Efficacy analysis was performed on the intention-to-treat population and
the studies reported numbers needed to treat (NNT), p-values, and confidence intervals (CI).
Table 1 shows the demographics and characteristic of the included studies.
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The first study by Cristofanilli et al. evaluated 521 women with any menopausal status
that had disease progression on previous anti-estrogen therapy. Women who had received a
previous CDK inhibitor, fulvestrant, everolimus or a P13K/mTOR pathway inhibitor were
excluded. The women were randomly assigned to receive palbociclib plus fulvestrant or placebo
plus fulvestrant. Oral palbociclib 125 mg or placebo were administered once daily for three
weeks followed by one week off, on a 28-day cycle. Fulvestrant was given to each groups on the
following schedule: 500 mg IM injection day 1 and day 15 of cycle 1, then day 1 of each
subsequent 28-day cycle. All premenopausal or perimenopausal women had to have started
treatment with a luteinizing-hormone-releasing-hormone agonist, goserelin, at least four weeks
before randomization. Additionally, during the treatment period, those women received goserelin
at the time of fulvestrant administration.
The second RCT by Hortobagyi et al. included 668 postmenopausal women with
recurrent or metastatic breast cancer who had not received prior systemic therapy for their
advanced disease. Measurable disease by Response Evaluation Criteria in Solid Tumors
(RECIST) had to be present or the patients had to have at least one predominately lytic bony
lesion. Additional inclusion criteria included an Eastern Cooperative Oncology Group
Performance Status of 0 or 1. Patients with inflammatory breast cancer or central nervous system
metastasis were excluded. Women were randomly assigned to receive either oral ribociclib plus
letrozole or letrozole plus placebo on the following regimens: 1) oral ribociclib 600 mg daily for
three weeks, followed by one week off, on a 28-day cycle plus oral letrozole 2.5 mg daily, or 2)
oral letrozole 2.5 mg daily plus placebo, and a schedule similar to those receiving ribociclib.
The final RCT by Finn et al. included 165 post-menopausal women who were selected to
participate if they had locally recurrent disease not amenable to surgery or evidence of metastatic
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disease; those with brain metastasis were excluded. The women were randomly assigned to
receive either palbociclib plus letrozole or letrozole alone. The following treatment regimens
were followed: 1) oral palbociclib 125 mg, given once daily for three weeks followed by one
week off, on a 28-day cycle plus oral letrozole 2.5 mg daily or 2) oral letrozole 2.5 mg daily.
Table 1. Demographics and characteristics of included studies
Study

Type

# pts

Age

Inclusion Criteria

Exclusion Criteria

W/D

Interventions

6

RCT

521

>18
yo

Menopausal
(natural or
medically
induced), ECOG
0-1, measurable
disease or bone
disease only,
relapse/progression
after previous
endocrine therapy
during tx or within
12 months, one
line of
chemotherapy in
advanced disease
was allowed

Received CDK
inhibitor,
fulvestrant,
everolimus,
P13K/mTO
inhibitor;
extensive
symptomatic
visceral mets;
uncontrolled CNS
mets

275*

Fulvestrant
500 mg IM
(day 1 & 15
of cycle 1;
then day 1 of
28-day cycle)
plus oral
palbociclib
125 mg (3 out
of 4 weeks)
vs. fulvestrant
IM plus
placebo

Finn4 (2015)

RCT

165

>18
yo

Received
letrozole within
12 months,
previous systemic
treatment for
advanced disease,
brain mets,
previous CDK
inhibitor

133*

Daily oral
letrozole 2.5
mg plus oral
palbociclib
125 mg (3 out
of 4 weeks)
VS. daily oral
letrozole

Hortobagyi7
(2016)

RCT

668

>18
yo

Post-menopausal,
ER+ advanced
disease, locally
recurrent tumor not
amenable to
surgery,
metastatic disease,
measurable tumor
by RECIST,
adequate organ
function
Post-menopausal,
locally HR+
recurrent or
metastatic disease,
measurable disease
per RECIST, one
predominant lytic
bone lesion

Inflammatory
disease, CNS
mets, previous
CDK inhibitor,
previous systemic
tx for advanced
disease

319*

Ribociclib
600 mg (3 out
of 4 weeks)
plus letrozole
2.5 mg daily
VS. placebo
plus letrozole

Cristofanilli
(2016)

*W/D due to objective progression or relapse, adverse events, withdrawal of consent, protocol, patient or physician
decision, global deterioration of health status, or death

5
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OUTCOMES MEASURED
All three studies primarily assessed morbidity and mortality based on progression-free
survival according to RECIST. This criterion defines when tumors in cancer patients improve,
stay the same, or worsen during the treatment course.
In the study by Cristofanilli et al., study treatment continued until disease progression,
unacceptable toxic effects, withdrawal of consent, or death. Tumors were assessed at baseline by
CT, MRI, or both, as well as every 8 weeks (+/- 7 days) for the first year and every 12 weeks
thereafter. Patients with only bone lesions had follow-up CT or MRI every 8 weeks during active
treatment for the first year, followed by every 12 weeks from the date of randomization.
Confirmation of complete response was also performed. To measure progression-free survival,
an audit approach with random sample-based, masked, independent central review was used.6 In
the study by Finn et al., tumor assessments were done by CT or MRI of chest, abdomen, and
pelvis at screening and every 8 weeks thereafter. Bone scans were performed, if applicable, at
baseline and then every 12 weeks. Progression-free survival was defined as time to radiological
disease progression from randomization or death on the study. 4 Hortobagyi et al. assessed tumor
response by CT or MRI at screening, every 8 weeks during the first 18 months, and every 12
weeks thereafter until disease progression, as well as at the end of treatment. An independent
review committee whose members were unaware of treatment assignments prospectively
reviewed all imaging data.7
RESULTS
The three RCTs evaluated in this selective review assessed the role of CDK4/6 inhibitors
in the treatment of advanced breast cancer. Cristofanilli et al. conducted a multicenter, doubleblind RCT that randomly assigned 521 women that progressed on previous endocrine therapy to
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either receive fulvestrant plus palbociclib (n=347) or fulvestrant plus placebo (n=174).
Administration schedule discussed in detail above. Assignments were made between October 7,
2013 and August 26, 2014 and overall survival follow-up is ongoing. By March 16, 2015, 259
progression-free survival events had occurred, 145 in the palbociclib group and 114 in the
placebo group.6 In the palbociclib group, median progression-free survival was 9.5 months (95%
CI 9.2-11.0), compared to 4.6 months (95% CI 3.5-5.6) in the control group.6 Best overall tumor
response for all participants was also assessed, and is described in Table 2 below. Clinical
benefit, defined as complete response plus partial response plus stable disease > 24 weeks, was
evaluated in both groups.6 Of the 347 subjects in the treatment group, 231 were identified as
having clinical benefit, while 69 out of the 174 participants in the control group had the same
classification.6 Absolute benefit increase for this study was 27% and numbers needed to treat
(NNT) equated to 4, with p-value statistically significant at <0.0001. Safety assessment included
patients who received at least one dose of study drug. The most common side effect in the
palbociclib group was neutropenia of any grade, occurring substantially more frequently than in
the control group at 81% and 3%, respectively.6 Additionally, infection, fatigue, nausea, other
blood dyscrasias, rash, and alopecia were more common in the palbociclib group. Serious
adverse effects accounted for a dose interruption in 54% of the treatment group versus 6% in the
placebo group.6 No deaths related to treatment toxicity occurred in either group. All subjects
were accounted for at the conclusion of the trial.
Table 2. Efficacy of Combination Therapy as Measured by Cristofanilli et al. 2016
Fulvestrant plus palbociclib
Clinical benefit*
95% Confidence Interval

Fulvestrant plus placebo

67%
40%
61.3-71.5
32.3-47.3
Treatment effect
CER
EER
RBI
ABI
NNT
p-value
0.40
0.67
0.675
0.27
4
<0.0001
*Clinical benefit in the intention-to-treat population is defined by complete response plus partial response plus stable
disease equal to or more than 24 weeks
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Between December 22, 2009 and May 12, 2012, Finn et al. randomly assigned 165
women to receive palbociclib plus letrozole (n=84) or letrozole alone (n=81). At the time of final
analysis, 41 progression-free events occurred in the treatment group, versus 59 in the control
group.4 Median progression-free survival was 20.2 months (95% CI 13.8-27.5) and 10.2 months
(95% CI 5.7-12.6), respectively.4 Of note, a greater proportion of patients had an objective
response to treatment and achieved clinical benefit in the palbociclib plus letrozole group
compared to those receiving only letrozole.4 This study also assessed overall survival at the time
of the final progression-free survival interval. In the palbociclib group, median overall survival
was 37.5 months (95% CI 28.4-NE) and 33.3 months (26.4-NE) in the letrozole group (HR
0.813, 95% CI 0.492-1.345; two-sided p=0.42).4 Similar to the other two studies, the most
common adverse effect in those receiving palbociclib was neutropenia. All patients who received
palbociclib plus letrozole had an adverse event, including leukopenia and fatigue, compared to
84% of patients who received letrozole alone; dose interruptions were required for 33% of the
combination group, compared to only 4% of the letrozole group.4 Despite the increase in adverse
events in the treatment group, this accounted for only 13% of discontinuation from the study,
versus 2% in the control group.4 Most discontinuations were secondary to progression of disease
and were more common in the patients receiving monotherapy, accounting for 70% of patients in
that group, versus 50% of patients on combination therapy.4
Table 3. Progression-free Survival with Combination Therapy vs Anti-estrogen
Monotherapy as Measured by Finn et al. 2016
Palbociclib plus letrozole
Median progression-free survival
95% Confidence Interval
Hazard ratio
95% Confidence interval
One sided p-value

20.2 months
13.8-27.5
Treatment effect

Letrozole alone
10.2 months
5.7-12.6

0.488
0.319-0.748
0.0004
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In the trial by Hortobagyi and colleagues, from January 24, 2014 to March 24, 2015, 668
post-menopausal women were randomly assigned to receive ribociclib plus letrozole (n=334) or
placebo plus letrozole (n=334) for first-line treatment of their recurrent or metastatic breast
cancer. Treatment regimens are noted above. By January 29, 2016, 349 patients were still
receiving treatment, 195 in the ribociclib group and 154 in the placebo group. 7 Of those that
discontinued treatment, progressive disease accounted for the reason in 26% of the ribociclib
group, versus 154 in the control group. For this study, a pre-specified interim analysis was
conducted when at least 211 patients progressed or died. It should be noted that the median
duration of progression-free survival was not reached in the ribociclib group, but was 14.7
months in the placebo group. After 18 months, however, progression-free survival was 63%
(95% CI 54.6-70.3) and 42.2% (34.8-49.5), respectively.7 These results were supported by
blinded central analysis. With the end-point of progression-free survival at 18 months, ABI is
20.8% with NNT=5. Similar to the study conducted by Cristofanilli discussed above, safety
analyses were evaluated in those patients that received at least one dose of a study regimen;
patients were also required to have at least one safety assessment after baseline. Dose
adjustments were permitted to manage treatment-related adverse reactions secondary to
ribociclib but not for letrozole. Neutropenia was the adverse event leading to the most dose
reductions in the ribociclib group (n=104). This effect was not observed in patients receiving
placebo.
Table 4. Efficacy of Ribociclib Plus Letrozole as Measured by Hortobagyi et al. 2016
Progression-free survival at 18
months
95% Confidence Interval
CER
0.422

EER
0.62

Ribociclib group

Placebo group

63%

42.2%

54.6-70.3%
Treatment effect
RBI
ABI
0.493
0.208

34.8-49.5%
NNT
5
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DISCUSSION
As previously discussed, breast cancer is a common malignancy effecting over 3 million
women in the United States. Treatment regimens for those with advanced disease are limited,
with no known cure available at this time. While endocrine therapy, surgery, radiation, and
chemotherapy offer some improvement in survival, drugs that target specific signaling pathways
must be considered as an alternative treatment option in patients at advanced stages of
malignancy. The study by Cristofanilli et al. showed an improvement in progression-free
survival, objective response, and clinical benefit in participants that received fulvestrant plus
palbociclib. This study evaluated the use of combination therapy in patients who failed previous
treatment, and the benefit was observed regardless of home many prior endocrine therapies they
had tried. Additionally, the level of expression of estrogen and progesterone receptors did not
significantly alter the above results.6 Hortobagyi’s and Finn’s analyses also showed the addition
of ribociclib or palbociclib to letrozole improved time until progression when initiated as firstline management for advanced breast cancer. Finn’s research also demonstrated clinically
significant benefit with combination therapy despite the patient’s menopausal status prior to
receiving treatment. A limitation to all studies was that dose reductions were necessary in a
higher proportion of the treatment group. Although the use of these novel agents is associated
with an increased risk of myelosuppression, the adverse events were manageable, and did not
appear to have a significant effect on the primary end-point for the studies. The above data
suggest that there is an important clinical role for the use of cyclin dependent kinase inhibitors in
the management of breast cancer.

Mercado, CDK 4/6 Inhibitors and Breast CA 11

CONCLUSIONS
This systematic review showed that the use of CDK4/6 inhibitors in combination with
anti-estrogen therapy improves progression-free survival in women with hormone receptorpositive, HER2neu negative advanced breast cancer compared to anti-estrogen therapy alone.
Clinical benefit was seen in all three studies irrespective of the choice of combination therapy
used. Finn and Hortobagyi described the role of CDK 4/6 inhibition plus anti-estrogen as a firstline treatment option, while Cristofanilli found the combination regimen to also be effective in
those who had progressed on previous endocrine therapies. For future studies regarding the use
of CDK 4/6 inhibitors, it would be beneficial to have a better understanding of the long-term
effects of prolonged use, specifically related to myelosuppression and bone marrow toxicity.
Finn addressed the question regarding efficacy in premenopausal as well as postmenopausal
women. This inclusion criterion could extend to future studies to increase generalizability of the
patient population.
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